Phase 2 Breast Cancer Trial, Recruiting NCT05635487 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05635487
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 to 75 years old
  • Your breast cancer has been confirmed through a tissue sample (biopsy) to be HER2-positive
  • Your breast cancer is at stage II or III and you have not yet received any treatment for it
  • You are generally able to carry out daily activities with little to no limitation (confirm with trial site)
  • Your organs such as your liver, kidneys, and heart are functioning at a good level (confirm with trial site)

Who may not be able to join:

  • You have already received any cancer treatment such as chemotherapy, radiation, targeted therapy, or hormone therapy
  • You are currently receiving any other cancer treatment at the same time as this trial
  • You have cancer in both breasts, inflammatory breast cancer, or a type where the original tumour cannot be found (occult breast cancer)
  • Your breast cancer has spread to other parts of the body (stage IV)
  • You have had any other type of cancer in the past 5 years, unless it was a fully cured cervical pre-cancer or a certain type of non-serious skin cancer
  • You have difficulty swallowing, ongoing diarrhoea, a bowel blockage, or any other condition that may affect how your body takes in medication
  • You have taken part in another clinical drug trial within the last 4 weeks
  • You have had an allergic reaction to any of the ingredients used in the treatments being studied in this trial
  • You have a significant lung condition or disease
  • You have a significant heart or blood vessel condition or disease
  • You have a history of immune system deficiency
  • You currently have active hepatitis or liver cirrhosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
16 March 2023
Est. completion
28 February 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Total pathological complete response (tpCR: ypT0-is/ypN0)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov